Paper Details

  1. Home
  2. Paper Details

Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa.

Author: AsanteKwaku Poku, AsiimweStephen, BarsainyaSarita, CsermakKatalin, DoumbiaSeydou, FofanaBakary, GandhiPreetam, GrobuschMartin P, HughesDavid, JainJay Prakash, KaritaEtienne, Kullak-UblickGerd A, MugerwaHenry, NdayisabaGilles, OduroAbraham, SchmittEsther K, SuGuoqin, YekaAdoke

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Cipargamin, a novel anti-malarial drug, demonstrated potent activity against Plasmodium falciparum. Although transient liver function test elevations were observed in previous trials, the drug was deemed safe at single doses of 10 to 150 mg and 10 to 50 mg daily for 3 days in this study. This was the first study on cipargamin conducted in sub-Saharan Africa.
Paper Details　
Original Abstract of the Article :
The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against Plasmodium falciparum. Transient asymptomatic liver function test elevations were previously observed in cipargamin-treated subjects in two trials: one in malaria patients in Asia and one in volunteers with experimentally...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686384/

データ提供：米国国立医学図書館（NLM）

Cipargamin: A New Hope for Malaria Treatment?

This research delves into the fascinating world of drug development, particularly focusing on a novel anti-malarial agent called cipargamin (KAE609). The study assesses the hepatic safety and tolerability of cipargamin in adult patients with Plasmodium falciparum malaria, a serious and potentially fatal parasitic infection. The researchers conducted a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa to evaluate the safety profile of cipargamin.

Cipargamin's Potential and Safety Considerations

This study provides evidence for the potential of cipargamin as a treatment for malaria. The results indicate that cipargamin exhibits potent and rapid activity against P. falciparum, offering hope for a new and effective treatment option for this debilitating disease. However, the study also highlights the need for careful monitoring of liver function, as transient asymptomatic liver function test elevations were observed in some patients.

The Quest for Effective Anti-Malarial Treatment

This study represents a step forward in the ongoing quest to develop effective treatments for malaria. It's like searching for a refreshing oasis in a vast desert. The findings provide evidence for the potential of cipargamin, but further research is needed to fully understand its safety profile and optimize its use in clinical practice. As with any medication, it's essential to consult with a healthcare professional to determine the appropriate treatment options for malaria.

Dr.Camel's Conclusion

As a researcher who has journeyed through the sands of medical history, I find this study a beacon of hope in the fight against malaria. Cipargamin holds promise as a powerful tool in our arsenal against this debilitating disease. While further research is needed to fully understand its safety and efficacy, the findings offer a glimpse of a brighter future for those affected by malaria.
Date :
  1. Date Completed 2022-11-10
  2. Date Revised 2022-11-10
Further Info :

Pubmed ID

34930267

DOI: Digital Object Identifier

PMC8686384

Related Literature

Article Analysis
・Effects of artemether and lumefantrine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.